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OBJECTIVES This study was designed to analyze the in-hospital and six-month clinical and angiographic
outcomes of patients with chronic renal failure (CRF) treated with intracoronary radiation for
the prevention of recurrence of in-stent restenosis.
BACKGROUND Patients with CRF are at a higher risk than the general population for accelerated
atherosclerotic cardiovascular disease and for restenosis after percutaneous coronary interven-
tion. Previous studies have shown the effectiveness of both beta and gamma radiation in
preventing recurrent restenosis in patients with in-stent restenosis.
METHODS We studied the in-hospital and six-month clinical and angiographic outcomes of 118 patients
with CRF and 481 consecutive patients without CRF who were treated with intracoronary
radiation for the prevention of recurrence of in-stent restenosis in native coronaries and
saphenous vein grafts.
RESULTS Patients with CRF were usually older, women, hypertensive and diabetic, with multivessel
disease and with reduced left ventricular function. In-hospital outcome for patients with CRF
was marred by a higher incidence of death, non–Q-wave myocardial infarction and major
vascular and bleeding complications. At six-month follow-up, the mortality rate was higher
in patients with CRF, 7.6% compared with 1.9% in non-CRF patients (p 5 0.003).
Restenosis, target lesion revascularization (TLR) and target vessel revascularization (TVR)
rates were similar in the two groups. In patients with CRF, radiation therapy compared to
placebo reduced restenosis (53.8% vs. 22.6%, p 5 0.04), TLR (71.4% vs. 15.3%, p , 0.0001)
and TVR (78.6% vs. 23.7%, p 5 0.0002).
CONCLUSIONS Intracoronary radiation for the prevention of recurrence of in-stent restenosis achieved similar
rates of restenosis and revascularization procedures in patients with and without CRF.
Despite this benefit, patients with renal dysfunction continued to have significantly higher
in-hospital and six-month adverse outcomes. (J Am Coll Cardiol 2001;38:1049–53) © 2001
by the American College of Cardiology
Patients with chronic renal failure (CRF) are at a higher risk
for cardiovascular complications, as they account for ;50%
of deaths among this patient population, with an annual
mortality rate of 18% to 20% (1–6). Recent data from our
experience and from other groups have shown that patients
with CRF are at a higher risk than the general population
for accelerated atherosclerotic cardiovascular disease and for
restenosis after percutaneous coronary intervention (PCI)
(7–10). Intracoronary radiation therapy with gamma- and
beta-emitting sources is a novel catheter-based procedure
that has demonstrated, in a series of prospective, random-
ized, double-blind trials, a reduction in the need for revas-
cularization procedures as well as in binary angiographic
restenosis rates in a broad range of patients with prior
in-stent restenosis (11–13). The objective of this report is to
analyze the efficacy of intracoronary radiation for the pre-
vention of recurrence of stenosis in patients with in-stent
restenosis and CRF and to compare their outcome to
patients with normal renal function who underwent intra-
coronary radiation for the prevention of in-stent restenosis.
METHODS
The WRIST Trials (Washington Radiation for In-stent
Restenosis Trial) are a series of different studies conceived at
the Washington Hospital Center. They were designed to
assess the benefit of intracoronary radiation (gamma and
beta) for the treatment of in-stent restenosis in both native
coronary arteries and in saphenous vein grafts. Details of
these trials (WRIST, LONG WRIST, BETA WRIST,
WRIST PLUS and COMPASSIONATE USE) have been
published previously (11,12,14,15). Briefly, all these trials
were sponsored by an Investigational Device Exemption
granted by the Food and Drug Administration and ap-
proved by the Institutional Review Board and Radiation
Safety Committee at the Washington Hospital Center.
These studies were monitored by an external data and safety
monitoring board, and an independent clinical event com-
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mittee that adjudicated all clinical events. Informed consent
was obtained from each patient before enrollment in any of
the trials. All patients underwent coronary intervention via
the transfemoral approach with conventional catheter-based
systems according to current guidelines (16). Weight-
adjusted heparin dosage was administered during the pro-
cedure in order to maintain an activated clotting time 250 to
300 s and routinely discontinued at the end of the proce-
dure. Patients received aspirin 325 mg at least 24 h before
the procedure and continued indefinitely afterwards. Pa-
tients were treated concomitantly with either ticlopidine
250 mg bid or clopidogrel 75 mg qd for four weeks per the
routine protocol. Clinical follow-up was performed at one,
three and six months. Angiographic follow-up was per-
formed at six months in 85.3% of patients. The occurrence
of major late clinical events was recorded, including death,
Q-wave myocardial infarction (MI) and revascularization
procedures, whether percutaneous or surgical. All events
were source documented and adjudicated by an independent
committee.
Study population. From the records of patients with in-
stent restenosis enrolled in these trials, we identified 118
patients with CRF and 481 patients without CRF who were
treated with intracoronary radiation for the prevention of
recurrence of in-stent restenosis. Angiographic entry criteria
included a diameter stenosis $50% within the stented area
in vessels 2.5 to 5.0 mm in diameter in patients who
underwent successful angioplasty (,30% residual diameter
stenosis in the absence of complications). Device selection,
including atheroablative devices (rotational and directional
atherectomy or excimer laser angioplasty), or additional
stents, were left at the discretion of the operator. Patients
with a recent MI (,72 h), left ventricular ejection fraction
,20%, prior irradiation to the chest, angiographic evidence
of thrombus or multiple lesions in the target vessel were
excluded from the studies. Quantitative coronary angio-
graphic analysis was performed by two independent core
laboratories blinded to the treatment protocols, and has
been described previously (11,14).
Definitions. Chronic renal failure was defined as the pres-
ence of previously documented renal insufficiency and/or
a baseline serum creatinine above the normal range
($1.4 mg/dl in women or $1.5 mg/dl in men) or a
creatinine clearance (CrCl) ,50 ml/min (17,18). Creatinine
clearance was calculated by applying the Cockcroft-Gault
formula (19) using the baseline serum creatinine: CrCl 5
[(140 2 age) 3 weight/serum creatinine 3 72] with female
gender adjustment (CrClfemale 5 CrCl 3 0.85). Procedural
success was defined as the absence of death, emergency
coronary artery bypass graft (CABG) or Q-wave MI.
Q-wave MI was defined by the presence of new pathological
Q waves in the electrocardiogram associated with an eleva-
tion of cardiac enzyme at least two times the upper normal
values. Non–Q-wave MI after the PCI was defined as a
creatine kinase-MB enzyme elevation $5 times the upper
normal value without new Q waves. Major bleeding was
defined as a reduction in hemoglobin .5 g/dl (or $15% in
hematocrit) or any intracranial bleeding. Major vascular
complications were defined as any retroperitoneal bleed,
pseudoaneurysm or fistula. Major adverse cardiac events
were defined as death, MI or target vessel revascularization
(TVR). Angiographic binary restenosis at follow-up was
defined as $50% diameter narrowing within the stent and
in the segment that included the stent plus its edges (within
5 mm). Late loss was defined as the minimal lumen
diameter immediately after the procedure minus the mini-
mal lumen diameter at the six-month angiographic follow-
up.
Radiation delivery and dosimetry. For the gamma radia-
tion, a 192-iridium source train was delivered into a non-
centering end-lumen catheter. The prescribed dose was
15 Gy to a distance of 2.0 mm from the surface of the source
for vessels between 2.5 and 4.0 mm or 15 Gy to a distance
of 2.4 mm for vessels .4.0 mm in diameter. Maximal dose
to the near wall was #45 Gy, whereas the minimum dose to
the far wall was #7.3 Gy. For the beta radiation, a
90-yttrium pure beta-emitter source was delivered into a
centering balloon end-lumen catheter. The prescribed dose
was 20.6 Gy to a distance 1.0 mm from the surface of the
inflated balloon. The dose rate varied from 16.0 to
5.6 Gy/min.
Statistical analysis. Data are presented as mean 6 stan-
dard deviation. For continuous variables, comparisons be-
tween the two groups were made with the Student t test and
for categorical values by the chi-square or Fisher exact test.
Target lesion revascularization (TLR) and TVR rates were
analyzed by Kaplan-Meier survival curves, with differences
between the two groups compared by the log-rank test.
Statistical analysis was performed with SAS software (SAS
Institute, Cary, North Carolina). A p value ,0.05 was
considered statistically significant.
RESULTS
Between February 1997 and January 2000, 719 patients
were enrolled in various in-stent restenosis radiation trials at
our institution. A total of 599 patients (118 with CRF and
481 with normal renal function) were assigned to radiation
therapy and 120 patients were assigned to the placebo arm
(14 with CRF and 106 without CRF). All patients pre-
Abbreviations and Acronyms
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sented with angina and had .50% in-stent restenosis either
in native coronaries or vein grafts. The baseline clinical
characteristics are shown in Table 1. Patients with CRF
were older and had more risk factors for coronary artery
disease than patients with normal renal function; they had
higher rates of female gender, hypertension, insulin-treated
diabetes and decreased left ventricular function. Angio-
graphic characteristics are shown in Table 2. There was a
higher percentage of multivessel disease and a trend towards
more diffuse disease in patients with CRF. Device use was
similar between the two groups; 50% of patients with CRF
underwent stenting, compared to 43% in the non-CRF
group, rotational atherectomy was performed in 43% versus
48% and 33% versus 26% underwent excimer laser angio-
plasty, respectively (p 5 NS).
Despite similar procedural success rates, in-hospital out-
come was significantly worse for patients with CRF, who
had higher vascular and bleeding complications, MI rates
and mortality, as shown in Table 3. Clinical events at
six-month follow-up are depicted in Table 4. Overall
mortality rates and cardiac death rates were significantly
higher in patients with CRF. Restenosis, TLR and TVR
rates by either coronary angioplasty or CABG were similar
between the two groups, although there was a trend towards
a higher rate of TLR and TVR by CABG in patients
without CRF. Late thrombosis rates were similar between
the two groups (0.8% in patients with CRF vs. 2.1% in
non-CRF patients, p 5 0.70).
Radiation versus placebo. During the performance of the
radiation trials, 120 patients were assigned to the placebo
arm; 14 (12%) of these patients had CRF. Comparison
between the radiated group and the control group in
patients with CRF detected similar baseline clinical, angio-
graphic and procedural characteristics and similar in-
hospital outcome. At six-months follow-up, the overall
mortality in the CRF group was high in both the irradiated
and the placebo-treated patients (7.6% and 7.1% respec-
tively, p 5 NS). In contrast, there was a 58% reduction in
binary restenosis in patients with CRF treated with radia-
tion compared with control, as shown in Figure 1. Rates of
TLR and TVR were also significantly lower in comparison
with the placebo arm. Patients with CRF treated with
placebo had a trend towards higher TLR rates (71.4% vs.
58.6%, p 5 0.34) and TVR rates (78.6% vs. 60.4%, p 5
0.18) compared with non-CRF patients treated with pla-
cebo, respectively. Restenosis rates were similar in both
groups (53.8% vs. 54.6%, p 5 0.83). Non-TVR rates were
similar in the radiation and the placebo arms (12.7% vs.
Table 1. Clinical Characteristics
CRF
(n 5 118)
Non-CRF
(n 5 481) p Value
Age (yrs) 71 6 11 60 6 10 , 0.0001
Female gender (%) 41.5 31.2 0.03
Unstable angina (%) 86.8 79.0 0.06
Diabetes (%) 44.1 38.8 0.29
Diet alone (%) 1.7 4.2 0.28
Oral hypoglycemic
drugs (%)
16.1 18.5 0.54
Insulin (%) 26.3 16.0 0.009
Hypertension (%) 84.7 69.6 0.0009
Hyperlipidemia (%) 87.2 86.1 0.77
Smoking history (%) 60.2 63.4 0.51
Prior myocardial
infarction (%)
53.4 52.4 0.85
Prior coronary bypass
surgery (%)
59.0 52.8 0.23
Baseline serum creatinine
(mg/dl)
2.01 6 1.76 0.98 6 0.19 , 0.0001
Creatinine clearance
(ml/min)
41.8 6 14.8 95.9 6 30 , 0.0001
Ejection fraction (%) 44 6 14 49 6 12 0.01
CRF 5 chronic renal failure.
Table 2. Angiographic Characteristics
CRF
(n 5 118)
Non-CRF
(n 5 481) p Value
Target vessel
Left main (%) 5.1 4.0 0.61
Left anterior descending (%) 21.2 22.5 0.77
Left circumflex (%) 24.6 24.7 0.97
Right coronary (%) 30.5 32.4 0.69
Saphenous vein graft (%) 18.6 16.4 0.56
Three-vessel disease (%) 44.1 32.4 0.02
Total occlusion (%) 8.9 9.8 0.83
Diffuse lesion (%) 80.6 68.1 0.14
Lesion length (mm) 21.8 6 9.3 23.2 6 12.2 0.38
Baseline
Reference vessel diameter
(mm)
2.56 6 0.58 2.65 6 0.62 0.21
Diameter stenosis (%) 64 6 16 66 6 15 0.60
Minimal lumen diameter
(mm)
0.91 6 0.45 0.92 6 0.43 0.24
Postprocedure
Diameter stenosis (%) 32 6 13 29 6 14 0.19
Minimal lumen diameter
(mm)
1.85 6 0.49 1.94 6 0.44 0.24
Diameter stenosis (%) 48 6 27 47 6 26 0.13
At six-month follow-up
Minimal lumen diameter
(mm)
1.54 6 0.80 1.48 6 0.79 0.67
Late lumen loss (mm) 0.48 6 0.77 0.50 6 0.75 0.62
Binary restenosis (%) 22.6 20.4 0.94
CRF 5 chronic renal failure.
Table 3. In-Hospital Clinical Outcome
CRF
(n 5 118)
Non-CRF
(n 5 481)
p
Value
Procedural success (%) 100 100 1
Death (%) 1.7 0 0.04
Myocardial infarction (%) 16.1 8.7 0.004
Q-wave (%) 0.8 1.2 1
Non–Q-wave (%) 16.1 7.5 0.004
Repeat angiography (%) 4.2 1.5 0.07
Repeat angioplasty (%) 1.7 0.4 0.18
Vascular complications (%) 18.2 5.6 , 0.001
Major bleeding (%) 16.4 2.3 , 0.0001
Major adverse cardiac
events (%)
18.6 10.4 0.01
CRF 5 chronic renal failure.
1051JACC Vol. 38, No. 4, 2001 Gruberg et al.
October 2001:1049–53 Intracoronary Radiation in Patients With CRF and In-Stent Restenosis
7.1%, p 5 0.98). Event-free survival (freedom from death,
MI and repeat revascularization) was significantly higher in
patients treated with intracoronary radiation, 72.9% versus
21.4% in the placebo group (p 5 0.0003).
DISCUSSION
The present study demonstrates that in patients with CRF
with in-stent restenosis, intracoronary radiation therapy
reduced the recurrence of in-stent restenosis and revascu-
larization procedures, but did not have an impact on the
incidence of MI, major vascular and bleeding complications
and short- and long-term mortality rates seen in these
patients. Despite the increased burden of risk factors in
patients with CRF compared with patients having normal
renal function, restenosis, TLR and TVR rates were similar
between both groups at six-months clinical and angio-
graphic follow-up.
Treatment of in-stent restenosis without radiation ther-
apy is associated with recurrence rates between 30% and
70%, regardless of the technique or device used. In the
present study, patients with CRF who had been randomized
to placebo had a trend towards higher revascularization rates
compared with non-CRF patients who had been random-
ized to placebo. These findings substantiate previous data
that have shown that patients with CRF have a higher
incidence of restenosis and cardiac events. In contrast, when
intracoronary radiation adjunctive therapy was delivered to
the treated lesion, the overall TVR and restenosis rates were
low, with no differences between CRF and non-CRF
patients. Thus, patients with CRF and in-stent restenosis
treated with intracoronary radiation for prevention of re-
stenosis achieved the same rates of restenosis, revasculariza-
tion procedures and event-free survival as non-CRF patients
treated with intracoronary radiation, equalizing their out-
come. Unfortunately, the robust reduction for the need of
revascularization procedures with intracoronary radiation
therapy did not affect the high mortality rates seen in
patients with CRF. Therefore, our study corroborates pre-
vious observations that reduction in restenosis rates and the
need for repeat revascularization procedures do not have an
effect on mortality, which is probably related to the nature of
the disease and obviously is not influenced by radiation
therapy.
Previous studies. The presence of CRF has been associ-
ated in previous studies with an increased risk for cardio-
vascular disease, generally attributed to the combination of
“traditional” atherogenic risk factors that are present in the
general population such as age, diabetes mellitus, hyperten-
sion, smoking and dyslipidemia with additional hemody-
namic and metabolic factors specifically related to the
uremic state, i.e., anemia, dyslipoproteinemia, hyperfibrino-
genemia and hyperhomocysteinemia, which develop in the
early stages of CRF (9,20,21). As shown in previous trials
and in our study (8,9,17,22), patients with CRF had a
higher prevalence of established risk factors for cardiovas-
cular disease, including older age, hypertension, insulin-
treated diabetes and reduced left ventricular function.
Figure 1. Binary restenosis rates, target lesion revascularization rates (TLR) and target vessel revascularization rates (TVR) at six-month angiographic
follow-up in chronic renal failure patients treated with either intracoronary radiation (white bar) or placebo (black bar).
Table 4. Clinical Outcome at Six Months
CRF
(n 5 118)
Non-CRF
(n 5 481)
p
Value
Death (%) 7.6 1.9 0.003
Cardiac death (%) 6.8 1.5 0.004
Myocardial infarction (%) 22.0 16.0 0.06
Q-wave (%) 0.0 1.2 0.60
Non–Q-wave (%) 22.0 14.8 0.06
TLR (%) 15.3 19.8 0.26
By PTCA (%) 12.7 13.9 0.73
By CABG (%) 2.5 7.3 0.06
TVR (%) 23.7 27.2 0.44
By PTCA (%) 20.3 20.2 0.97
By CABG (%) 4.2 9.1 0.08
MACE free (%) 72.9 71.5 0.77
Late total occlusion (%) 5.1 6.2 0.64
CABG 5 coronary artery bypass surgery; CRF 5 chronic renal failure; MACE 5
major adverse cardiac events (death, myocardial infarction and target vessel revascu-
larization); PTCA 5 percutaneous transluminal coronary angioplasty; TLR 5 target
lesion revascularization; TVR 5 target vessel revascularization.
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Study limitations. The present study was a retrospective
analysis and, therefore, the results and conclusions are
subject to the limitations inherent in all such reports. The
current analysis was not prespecified at the time of protocol
design and, thus, the absence of significant differences
between the groups can be attributed to beta-type statistical
error. Although clinical follow-up was obtained in all
patients, angiographic follow-up was completed in a smaller
percentage of patients. Although trial data support the use
of glycoprotein IIb/IIIa inhibitors in patients undergoing
PCI, ,10% of patients received this treatment. In view of
the higher incidence of non–Q-wave MI in patients with
CRF, maybe these patients would have benefited from such
a therapy. Finally, the relatively small number of patients in
the CRF arm, especially in the placebo arm, may also lead
us to incur a type II statistical error.
Clinical implications. Despite the high degree of proce-
dural success that may be achieved in the present interven-
tional era, patients with CRF with in-stent restenosis
represent one of the most demanding patient populations to
treat. The increased number of risk factors seen in these
patients, combined with severe and diffuse disease and a
high incidence of in-hospital and long-term complications,
make PCI in these patients particularly challenging. The use
of intracoronary radiation in patients with CRF with
in-stent restenosis provides hope for reducing the need of
revascularization procedures, and should be considered the
treatment of choice. Despite this benefit, patients with renal
dysfunction continued to have significantly higher in-
hospital and six-month adverse events.
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